Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi's Jevtana still too expensive for NICE, despite end-of-life credentials rethink

This article was originally published in Scrip

Executive Summary

NICE, the health technology appraisal institute for England and Wales, maintains that Sanofi-Aventis’ docetaxel follow-on Jevtana (cabazitaxel) is too costly for treating prostate cancer patients on the National Health Service. Final negative draft guidance comes even though the institute changed its mind and recognised that the drug does in fact meet NICE's end-of-life criteria that gives it more scope to consider expensive drugs.

You may also be interested in...



Can Biosimilar Orphans Increase Health System Sustainability In The UK?

Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.

Brazil Authorizes Oxford/AZ and Sinovac Vaccines

In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.

Success For Dutch Parallel Registration and Reimbursement Pilot

A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel